Beta blockers in HF, reduced EF And Increased HR
Abstract
Care for cardiac patient has been revolutionized throughout the past decades. Despite its initiated safety concerns, beta blockers are now one of the most used and safer drugs for the ailment of heart failure. These have proved not only effective for heart failure but also for many other conditions such as migraine headaches, breast cancer to reduce the mortality etc.
Keywords: beta blockers, heart failure with reduced ejection fraction, heart rate
Keywords:
beta blockers, heart failure with reduced ejection fraction, heart rateDOI
https://doi.org/10.22270/jddt.v12i6.5730References
Martinez-Milla J, Raposeiras-Roubin S, Pascual-Figal DA, Ibanez B. Role of beta-blockers in cardiovascular disease in 2019. Revista Española de Cardiología (English Edition). 2019 Oct 1; 72(10):844-52. https://doi.org/10.1016/j.rec.2019.04.014
Weber MA. The role of the new β-blockers in treating cardiovascular disease. American journal of hypertension. 2005 Dec 1; 18(S6):169S-76S. https://doi.org/10.1016/j.amjhyper.2005.09.009
Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox KM, CLARIFY investigators. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PloS one. 2012 May 3; 7(5):e36284. https://doi.org/10.1371/journal.pone.0036284
-Volnes T, Westheim A, Gullestad L, Slind EK, Grundtvig M. β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry. Biomedicine hub. 2020; 5(1):1-0. https://doi.org/10.1159/000505474
Lee PH, Park GM, Han S, Kim YG, Lee JY, Roh JH, Lee JH, Kim YH, Lee SW. Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management. Scientific reports. 2020 Dec 17; 10(1):1-9. https://doi.org/10.1038/s41598-020-79214-0
D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJ, Manzano L, Boehm M, Van Veldhuisen DJ. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology. 2017 Jun 20; 69(24):2885-96. https://doi.org/10.1016/j.jacc.2017.04.001
Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. Journal of clinical oncology. 2011 Jul 1; 29(19):2635-44. https://doi.org/10.1200/JCO.2010.33.5422
Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. Indian Journal of Dermatology, Venereology and Leprology. 2017 May 1; 83(3). https://doi.org/10.4103/ijdvl.IJDVL_220_16
Kallistratos MS, Poulimenos LE, Manolis AJ. Vasodilator β-blockers: a different class of antihypertensive agents?. Future Cardiology. 2014 Nov; 10(6):669-71. https://doi.org/10.2217/fca.14.51
Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. Journal of the American College of Cardiology. 2009 Jan 13; 53(2):184-92. https://doi.org/10.1016/j.jacc.2008.09.031
JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, Manzano L, McMurray JJ, Ruschitzka F, Van Veldhuisen DJ, Von Lueder TG. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European heart journal. 2018 Jan 1; 39(1):26-35. https://doi.org/10.1093/eurheartj/ehx564
Karwath A, Bunting KV, Gill SK, Tica O, Pendleton S, Aziz F, Barsky AD, Chernbumroong S, Duan J, Mobley AR, Cardoso VR. Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. The Lancet. 2021 Oct 16; 398(10309):1427-35. https://doi.org/10.1016/S0140-6736(21)01638-X
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta‐blockers for hypertension. Cochrane database of systematic reviews. 2017(1). https://doi.org/10.1002/14651858.CD002003.pub5
Fekadu G, Bekele F, Bekele K, Hanbisa S, Belay G, Maqbool M. Drug Use Evaluation of Beta-Blockers in Medical Wards of Nedjo General Hospital, Western Ethiopia. Cardiovascular Therapeutics. 2020 Jun 1; 2020. https://doi.org/10.1155/2020/2509875
Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta‐blockers for chronic obstructive pulmonary disease. Cochrane database of systematic reviews. 2005(4). https://doi.org/10.1002/14651858.CD003566.pub2
Paolillo S, Dell'Aversana S, Esposito I, Poccia A, Filardi PP. The use of β-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. European Journal of Internal Medicine. 2021 Jun 1; 88:9-14. https://doi.org/10.1016/j.ejim.2021.03.035
Chupp GL. Say what, beta-blockers for asthma?. American Journal of Respiratory Cell and Molecular Biology. 2008 Mar; 38(3):249-50. https://doi.org/10.1165/rcmb.2008-0001ED
Eldrup-Jorgensen J. Measuring quality and the story of beta blockers. Journal of vascular surgery. 2011 Mar 1; 53(3):845-55. https://doi.org/10.1016/j.jvs.2010.11.091
Ostrowska M, Kubica J. Carvedilol-is it still the primus inter pares among b-blockers?. Medical Research Journal. 2018; 3(3):165-74. https://doi.org/10.5603/MRJ.2018.0028
Thalheimer U, Bosch J, Burroughs AK. An apology for beta blockers. Journal of hepatology. 2014 Aug 1; 61(2):450-1. https://doi.org/10.1016/j.jhep.2014.03.040
Chrysant SG, Chrysant GS. Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective. Hospital Practice. 2022 Feb 13(just-accepted). https://doi.org/10.1080/21548331.2022.2040920
Chourdakis E, Koniari I, Velissaris D, Tsigkas G, Kounis NG, Osman N. Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. Journal of Geriatric Cardiology: JGC. 2021 May 5; 18(5):362.
Niriayo YL, Asgedom SW, Demoz GT, Gidey K. Treatment optimization of beta-blockers in chronic heart failure therapy. Scientific Reports. 2020 Sep 28; 10(1):1-8. https://doi.org/10.1038/s41598-020-72836-4
Deliver E, Mayor Jr F, D'Ocon P. Beta-blockers: historical perspective and mechanisms of action. Revista Española de Cardiología (English Edition). 2019 Oct 1; 72(10):853-62. https://doi.org/10.1016/j.rec.2019.04.006
Published
Abstract Display: 364 
PDF Downloads: 390 PDF Downloads: 47 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.